Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
168 hedge funds and large institutions have $1.08B invested in Intercept Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 54 increasing their positions, 49 reducing their positions, and 27 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
52% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 27
45% more call options, than puts
Call options by funds: $82.9M | Put options by funds: $57.2M
10% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 49
8% more funds holding
Funds holding: 155 → 168 (+13)
1% more capital invested
Capital invested by funds: $1.08B → $1.08B (+$6.39M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$65.7M |
| 2 |
SM
Senvest Management
New York
|
+$24.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$22.2M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$19.2M |
| 5 |
PA
Pinnacle Associates
New York
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$81.9M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$43.5M |
| 3 |
O
OrbiMed
New York
|
-$22.4M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$15.7M |
ICPT Hedge Fund Activity: Q4 2017 in Review
168 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q4 2017, worth a combined $1.08B — up 0.59% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new ICPT positions and 27 closed out — a net gain of 14 holders — while 54 added to existing stakes and 49 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $65.7M. The largest seller was Ameriprise, cutting an estimated $81.9M.
- 168 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q4 2017, up from 155 in Q3 2017.
- Funds reported $1.08B of Intercept Pharmaceuticals, Inc. stock for Q4 2017, up 0.59% quarter-over-quarter.
- 41 funds opened new Intercept Pharmaceuticals, Inc. positions in Q4 2017 and 27 closed out, a net change of +14 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q4 2017 was JP Morgan Chase, an estimated $65.7M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q4 2017 was Ameriprise, an estimated $81.9M sold.
Based on aggregated 13F filings for Q4 2017.